Find an expert

Dr Jenny Fung is a senior postdoctoral research fellow and lecturer of pharmacology course at the School of Biomedical Sciences (SBMS), UQ. She is an emerging researcher in the reproductive disease field with experience in molecular biology techniques, genetics, functional genomics, statistical and high-throughput computational skills, ex-vivo and in-vivo models of diseases, as well as industry engagement. In 2013, she was awarded a PhD at UQ and continued post-doctoral research in Professor Grant Montgomery's laboratory at QIMRB and IMB, in the field of genetics and genomics with a focus on functional genomics studies in complex diseases and a special interest in endometriosis. Her research has led to the seminal publication identifying the genetics of gene expression in endometrium and the role of gene regulation underlying endometriosis-related pathogenesis. In 2019, she joined Professor Trent Woodruff’s laboratory at SBMS, UQ to work on immunotherapy development for cancer through funding from Pfizer, where she performed immune cell functional assays and genomics analyses. Dr Fung is in a unique position to perform both the wet and dry lab components of multi-disciplinary research. She is currently co-leading multiple projects, where she is contributing her expertise on genetics and functional genomics on immunology to discover target genes and putative pathways underlying disease progression, with an ultimate goal to develop potential effective drugs for reproductive and brain disorders.

Dr. Richard Gordon leads a multi-disciplinary, industry-partnered research program in Translational Neuroscience which integrates immunology, drug development, pharmacology, metabolomics and microbial metagenomics. His group aims to understand and therapeutically target key pathological mechanisms which drive the onset and progression of neurodegenerative disorders such as Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Their work combines target validation studies in human patients with mechanistic insights from disease models to develop and test novel therapeutic strategies that can be translated towards clinical trials.

Key research themes within this program include:

• Understanding how chronic immune and inflammasome activation contribute to neurodegeneration in the CNS
• The role of gut dysbiosis and gastrointestinal dysfunction in Parkinson’s disease pathophysiology
• Therapeutic targeting of the gut-brain axis for neuroprotection
• Drug discovery, development and repositioning for novel therapeutic targets
• Discovery and validation of clinical biomarkers for PD and ALS
• Clinical trials for disease-modifying therapeutic strategies

Dr Christian Gray joined the Academy of Medical Education as a Senior Lecturer in 2019 and is a course coordinator and module lead. Prior to this, Dr Gray was a Lecturer in Infection and Immunity and was Immunology discipline lead at Peninsula Medical School at the University of Plymouth, Devon, UK.

Dr Gray has previously undertaken Postdoctoral research in a variety of areas in immunological research including therapies for rheumatoid arthritis, pneumococcal vaccines, mastitis resistance in dairy cattle, and vaccines for R. microplus. He obtained his PhD from the University of Newcastle, Australia in 2002. He was the first to identify a link between activation of regulatory T cells and the suppression of the immune system in patients with melanoma.

Within his current role he have transferred his skills from biomedical research into pedagogy of teaching and learning. He is actively developing a research portfolio within medical research focusing on the support of student learning.

Judith Greer is an immunologist with a strong interest in the nervous system and autoimmune diseases affecting the nervous system.

She is a graduate of the University of Queensland, having completed her PhD on cancer immunology. She then undertook postdoctoral training at Harvard Medical School in the USA, during which time her interests shifted towards immune responses and interactions within the nervous system (neuroimmunology), an area in which she has worked ever since. She isa Principal Research Fellow at the UQ Centre for Clinical Research, located at the Royal Brisbane & Women's Hospital.

Her research is directly particularly towards trying to identify brain components that are targetted by the immune system in people with a variety of disorders, particularly multiple sclerosis (MS), which is traditionally thought to be an autoimmune disease, but also in psychosis, where we are now starting to understand that autoimmune targetting of the brain can play a role in some patients. She is interested in how the specificity of autoimmune responses within the nervous system relates to the symptoms experienced by patients, and in developing new ways to specifically turn off the damaging immune responses in the brain. Another focus of her research is to improve on pre-clinical models of MS, so as to enhance the translation of new therapeutic approaches for MS to the clinic.

Judith is also interested in research training, and held leadership positions in this area in the School of Medicine and the Faculty of Medicine at UQ from 2000 - 2023. She is also committed to improving the field of neuroimmunology, and has been a member of the International Advisory Board of the International Society for Neuroimmunology and is the Asia-Pacific representative for the Global Schools of Neuroimmunology. Judith co-founded a society, Neuroimmunology Australia, to better support those working in this field, and was Convenor and Chair of the 14th International Congress of Neuroimmunology, which was held in Brisbane in 2018 (the only time this congress has been held outside of the Northern Hemisphere).

Dr. Wenyi Gu’s early education was conducted in China which include his undergraduate and master’s degrees in veterinary medicine. In 1996, he migrated to Australia and pursued his PhD study in biochemistry & molecular biology at the Australian National University (ANU). After a short period of work at John Curtin Medical School ANU as a junior scientist, he moved to Brisbane in 2001 for his post-doc at the University of Queensland and currently a post-doctoral research fellow at AIBN. He held a Peter Doherty Fellowship (2006-2009) and was further supported by NHMRC to spend 7 months at Harvard University as a visiting fellow in 2008. Since his post-doctoral research he has been working in the area of using RNAi to treat viral diseases and cancers. He also has a strong background in immunology and vaccine development.

I lead a research program with extensive expertise in immunology, particularly in natural killer (NK) cells, focused on developing innovative approaches for treating hard-to-cure diseases like metastatic cancers. Our mission is to improve patient outcomes and extend lives. My research group is based at the Translational Research Institute (TRI).

My dedication to my field has been recognized through numerous peer-reviwed grants as sole-CI or CIA/Principal Investigator, including a NHMRC ECF Peter Doherty Fellowship, an NHMRC Project Grant, an US DoD, a MRFF EMCR among others. Since 2009, I've amassed an impressive portfolio of 96 publications in renowned journals like Blood, Cell Death Dis, JEM, PNAS, Nat Comms, and Nat Immunol with an H-index = 40. My body of work and contributions have been acknowledged with awards such as the 2019 Researcher of the Year by CCA, 2020 QLD Young Tall Poppy Science, 2020 UQ Frazer Institute's Rising Star, 2022 Frazer Institute's Mentor of the Year, 2023 Translational Research Institute - Connecting with the Clinic among others. Recognized as an international leader in my field, I've been instrumental in identifying novel regulators of our immune functions, and developing NK cell-based immunotherapies.

At present, I am a Group Leader / Principal Research Fellow & Associate Professor with the University of Queensland's Frazer Institute. Here, I lead a high-performing research team with a keen focus on developing and innovating immunotherapy approaches for a spectrum of diseases.

Associate Professor Emma Hamilton-Williams’ career focuses on understanding how immune tolerance is disrupted leading to the development of the autoimmune disease type 1 diabetes. She received her PhD from the Australian National University in 2001, followed by postdoctoral training in Germany and the Scripps Research Institute in the USA.

In 2012, she started a laboratory at the Frazer Institute, University of Queensland where she investigates the gut microbiota as a potential trigger or therapy target for type 1 diabetes, as well as developing an immunotherapy for type 1 diabetes. The overall aim of her research is to find new ways to prevent or treat the underlying immune dysfunction causing autoimmunity.

She is Chief Scientific Officer for an Australia-wide pregnancy-birth cohort study of children at increased risk of type 1 diabetes, which aims to uncover the environmental drivers of this disease. Her laboratory uses big-data approaches including proteomics, metabolomics and metagenomics to understand the function of the gut microbiota linked to disease.

She recently conducted a clinical trial of a microbiome-targeting biotherapy aimed at restoring a healthy microbiome and immune tolerance, with an ultimate aim of preventing type 1 diabetes.

I am a Research Fellow and Leader in Pain Relief Innovation at AIBN, UQ. My research interests sit at the interface of drug delivery and the pain field. My overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management. I am looking for highly motivated postgraduate students.

I also enjoy volunteering within the academic community, most notably as Head of the SBMS ECR Committee and Treasurer for The Queensland Chinese Association of Scientists and Engineers (QCASE). I am currently serving as guest editor of Pain Research and Management.and JoVE Methods Collection.

Research Interests

My research is focusing on nano-based drug formulation and development to improve chronic pain management. I have a broad and unique background in both pharmacology and drug delivery systems, with specific expertise in the development of novel drug products and testing their analgesic efficacy and safety including pharmacokinetic and pharmacodynamic studies. To date, I have established five different techniques to produce painkiller–loaded nanoparticles and nanofibers aimed at improving pain relief for patients where currently available pain-killers either lack efficacy or produce dose-limiting side-effects. For example, there is a small and very potent peptide that has been on the market as a chemical for over 10 years but which cannot be used as a therapeutic due to its short half-life and poor oral bioavailability. In the form of my nanoparticles, that peptide has the potential to become an oral treatment for improving pain management in patients whose pain is currently poorly alleviated by clinically used pain-killers. I have significant expertise in the use of rodent pain models to assess novel analgesics, and I have received excellent training in conducting research in accordance with the stringent requirements of the Quality Management System (quality accreditations (GLP and ISO17025) from NATA). Together, my knowledge, skills and experience will facilitate the efficient translation of my research from the bench to the clinic.

The current focus of the lab is on the development of drug-products to solve one of the largest unmet medical needs in the pain field through use of sustainable materials. 1) We are developing multifunctional sutures including biodegradable pain relief sutures. 2) We are developing my innovative novel nanoparticles, which deliver innate-immune targeting peptides for the treatment of cancer and cancer-related pain. We are establishing a platform for the development of safe, effective delivery for other small molecule peptide drugs in general to pave their way to clinical trials. 3) Our research also investigates the role of C5a and C3a, estrogen, etc. in the pathogenesis of chronic pain including neuropathic pain, cancer-related pain, low back pain and OA pain.

We work in collaboration with other leading Australian and international researchers to stay at the forefront of the drug delivery systems field and the pain field. We also provide preclinical evaluation of novel compounds and formulations.

Professor Geoff Hill MBChB MD BHB FRCPA FRACP geoffH@qimr.edu.au

NHMRC Australia and QLD Health Senior Clinical Research Fellow

Coordinator, Cancer Programme, QIMR Berghofer

Head, Bone Marrow Transplantation Laboratory, QIMR Berghofer

Director of Research, Cancer Care Services, Royal Brisbane & Womens’ Hospital

Bone Marrow Transplant Physician and Haematologist, Royal Brisbane & Womens’ Hospital

Geoff Hill is a medical graduate of the University of Auckland and Haematologist, training in New Zealand, The Dana Farber Cancer Institute in Boston. He is a NHMRC Australia Fellow and his immunology laboratory focuses on the interactions between cytokines, antigen presenting cells and regulatory T cells during transplantation.

Professor Hill was the 2005 Queenslander of the Year and recipient of the Transplantation Society of Australia and New Zealand 2009 Ian McKenzie Award and the 2014 Translational Research Institute National Prize for excellence within basic and clinical research in the transplant field. He was also awarded a Queensland Health Senior Clinical Research Fellowship in 2010 to translate new cytokine and cell based therapies into clinic practice.

The research interests of the Hume Laboratory centre on the biology of macrophages and osteoclasts. These are cells of haematopoietic origin that are closely related to each other but have distinctly different activities.

David Hume was a group leader at the Institute for Molecular Bioscience (1988-2007) and subsequently Director of the Roslin Institute at the University of Edinburgh in Scotland from 2007-2017. He is currently a Professorial Research Fellow at the Mater Research Institute-UQ, located at the Translational Research Institute

Researcher Biography

Dr Snehlata Kumari is the head of skin inflammation and immunity laboratory at the Frazer Institute, the University of Queensland in Brisbane, Australia. She is a board member of the Australasian Society for Dermatology Research (ASDR).

After PhD and post-doctoral training in Germany, she is heading her research group with a focus on elucidating molecular mechanisms and underlying signalling pathways regulating inflammation. She has discovered novel mechanisms by which NF-kappaB, TNF, necroptotic and apoptotic signalling pathways control skin homeostasis and inflammation and published in top-tier journals such as Nature and Immunity.

Her scientific contributions received recognition from the global immunology and dermatology scientific communities including the German National Academy of Sciences, German Research Foundation (SFB), European Society for Dermatological Research, and the 2021 Christina Fleishmann Award for the Young Women Investigator from the International Cytokine and Interferon Society, USA

Overall aims and research focus

- Understanding molecular mechanisms of epithelial and immune cell communication in skin homeostasis and immunity.

- Elucidating signalling pathways and cytokines/chemokine interactions to develop novel drug targets and strategies to treat skin diseases such as Psoriasis, Hidradenitis Suppurative, Atopic Dermatitis.

Dr. Larisa Labzin studies how our innate immune system detects viral infections and how it decodes different signals to mount an appropriate immune response. Dr. Labzin's interest in innate immunity started during her honours training with Prof. Matt Sweet at the IMB, looking at how inflammatory signalling is regulated in macrophages. After gaining more experience while working as a research assistant for Prof. Sweet, she moved to Germany to the University of Bonn for her PhD. At the Univeristy of Bonn, Dr. Labzin investigated the anti-inflammatory effects of High-Density Lipoprotein with Prof. Eicke Latz. Here she discovered novel regulatory pathways that control inflammation. Dr. Labzin then moved to Cambridge, UK as an EMBO postdoctoral fellow to work with Dr. Leo James at the Medical Research Council Laboratory for Molecular Biology. In Dr. James' lab Dr. Labzin focused on how viruses are sensed by the innate immune system to trigger inflammation. In particular, Dr Labzin investigated how antibodies change the way viruses trigger inflammation. While in Cambridge, Dr. Labzin was awarded an NHMRC CJ Martin Fellowship to return to Australia. Larisa returned to the IMB in September 2019 to work with Prof. Kate Schroder. Dr. Labzin is an IMB Fellow and leads an independent research team studying inflammation in response to influenza and SARS-CoV-2.

Dr Lee is a mid-career researcher with training in neuroscience, and additional experience in pharmacology and immunity. He completed his Ph.D. at the University of Queensland (UQ) in 2014 and continued his post-doctoral research studies in neuroinflammation and neurodegenerative diseases. He is currently a Senior Research Fellow and Group Leader at UQ's School of Biomedical Sciences, where he focusses on innate immune and inflammatory pathways including the complement system and inflammasomes in motor neuron disease (amyotrophic lateral sclerosis), Huntington’s disease, and Parkinson’s disease. Dr Lee’s research has demonstrated the therapeutic potential of multiple anti-inflammatory drugs targeting innate immune-mediated neuroinflammation to reduce neuronal cell death in animal models of neurodegenerative disease. He is also interested in the links between the immune system, stress response, and energy metabolism in neurodegeneration.

Dr Odette Leiter is a postdoctoral research fellow in the research group of Dr Tara Walker, investigating systemic brain rejuvenation. She was awarded a PhD in Neuroscience in 2018 by the Technische Universität Dresden in Germany. Her research focus lies on the regulation of adult hippocampal neurogenesis by physical exercise, a process critically involved in learning and memory.

To support her research at the Queensland Brain Institute, Dr Odette Leiter has received two postdoctoral fellowships, a postdoctoral fellowship from the German Academic Exchange Service, followed by a Walter Benjamin Fellowship awarded by the German Research Foundation, allowing her to investigate the role of platelets in mediating neurogenesis-related learning and memory, and the capacity of platelet-released factors to restore cognitive function in ageing. More recently, Dr Leiter has been awarded a Discovery Early Career Researcher Award (DECRA) to investigate the precise mechanisms through which platelets interact with adult hippocampal neural stem cells following exercise.

Dr. Sherman Leung is the Head of Research Operations at Wesley Research Institute - the research partner of UnitingCare. UnitingCare is the largest private employer in Queensland, encompassing four hospitals (The Wesley Hospital, St. Andrew's War Memorial Hospital, Buderim Private Hospital and St. Stephen's Hospital), as well as significant community-based offerings through Lifeline, Blue Care, Family and Disability Services, and ARRCS.

Dr. Leung is a PhD trained scientist, conducting his research training at Mater Research Institute, The University of Queensland, during which his research was published in highly regarded peer-reviewed journals, including in 'Diabetes', receiving the Cover Image, an 'In This Issue' feature, and shared across the Australian-wide 7 Network news.

He has extensive experience in clinical trials, having worked at Microba Life Sciences, an ASX-listed biotechnology start-up, and Nucleus Network, Australia’s largest early phase clinical trial site having overseen the conduct of several high-profile COVID-19 projects including Nuvaxovid by Novavax that has been granted emergency authorisation in 40 countries including by the TGA, EMEA & FDA.

He contributes his spare time to the greater good through numerous initiatives in the industry including being a Board Director of the Australian Clinical Trials Alliance (ACTA), Editorial Board for 'Trials' – a BMC journal promoting all aspects of trials including methods, processes and non-significant outcomes for transparency in the field – being a former member of the Metro North Human Research Ethics Committee (HREC), and offering regular guest classrooms on clinical trials, informed consent and ethics at The University of Queensland.

Junxian Lim is an accomplished molecular biologist at the Institute for Molecular Bioscience. With a strong background in cell biology, protein biochemistry, and pharmacology, he has established himself in the field. Collaborating with researchers at universities, institutions, as well as international industry partners like AstraZeneca and Sosei Heptares, he has contributed significantly to advancing scientific knowledge.

Throughout his doctoral studies, Junxian authored seven ground-breaking studies focused on the development of novel bioactive inhibitors targeting immune cells and inflammatory diseases. These contributions have paved the way for innovative approaches to drug development. Utilizing his expertise, he has successfully developed and characterized a diverse range of protein and cellular assays that enable in-depth investigations into immunity and inflammation. His research findings have been published in prestigious scientific journals, including Nature Communications, Cell Reports, Journal of the American Chemical Society, Diabetes, Journal of Medicinal Chemistry, and the British Journal of Pharmacology. His work has been highly cited, reflecting its impact and significance within the scientific community.

Recognized for his outstanding mentoring abilities, Junxian has supervised or co-supervised the research of two completed PhD students, six completed MPhil students, and three completed Honours students. The success of his former students is a testament to his dedication and guidance. They continue to excel and actively contribute to research endeavours around the world, spanning countries such as Australia, Singapore, Korea, India, Japan, and China.

Beyond his research and mentoring achievements, Junxian actively participates in the scientific community. He serves on the editorial boards of esteemed journals like Journal of Translational Medicine, Frontiers in Molecular Biosciences and Biology. This involvement allows him to stay at the forefront of scientific advancements and contribute to the dissemination of knowledge within his field.

Over 5 years of experience in translational biomedical research, specialising in monoclonal antibody-based therapies, immuno-oncology, target discovery and theranostics in cancer. My main research focus is on targeted cancer therapies, understanding how target receptor endocytosis affects antibody drug conjugate (ADC) and radioligand therapy delivery, immune-mediated ADCC, and how combination therapies with immune checkpoint inhibitors can potentially improve therapeutic outcomes for patients.